MRK vs XRAY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
XRAY exhibits severe fundamental weakness, highlighted by a critical Piotroski F-Score of 2/9, indicating poor financial health and operational deterioration. While valuation metrics like the Forward P/E (7.67) and Price/Sales (0.65) appear attractive, they are overshadowed by a -16.25% profit margin and a catastrophic recent earnings miss (Surprise: -4027.8%). The stock is in a long-term structural decline, losing 80% of its value over five years, and the technical trend is completely bearish (0/100). Despite a decent dividend yield, the underlying lack of profitability makes the current valuation a likely value trap.
Compare Another Pair
Related Comparisons
MRK vs XRAY: Head-to-Head Comparison
This page compares Merck & Co., Inc. (MRK) and DENTSPLY SIRONA Inc. (XRAY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.